| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ff283c7d6797987f01db547f606e6b32
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7970e52ae37d06074d5f8d1b8a857bf5 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2500-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-136
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-158
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6876
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6893
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7088
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39541 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P19-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-6876
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7088 |
| filingDate |
2019-11-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8172c620a6d37af2a91b3f16f273a918
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8975a2685dbf87005bc81631dc0a91ec |
| publicationDate |
2021-05-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
KR-20210054890-A |
| titleOfInvention |
Pharmaceutical composition for the prevention or treatment of arthritis comprising the expression or activity inhibitors of ion transporter SLC4A7 as an active ingredient |
| abstract |
It relates to a pharmaceutical composition for the prevention or treatment of arthritis containing an expression or activity inhibitor of the ion transporter SLC4A7 as an active ingredient, and the pharmaceutical composition provided in one aspect of the present invention not only inhibits the expression or activity of the ion transporter SLC4A7. In addition, by suppressing the expression of bone destruction factors, cell mobility factors, etc., there is an excellent effect in preventing or treating joint deformation and preventing or treating diseases related to bone inflammation. |
| priorityDate |
2019-11-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |